tiprankstipranks
Advertisement
Advertisement

HK:2617 Stock Latest News

TransThera to Showcase Tinengotinib Phase II Data in FGFR2-Altered Cholangiocarcinoma at 2026 ASCO
Company AnnouncementsTransThera to Showcase Tinengotinib Phase II Data in FGFR2-Altered Cholangiocarcinoma at 2026 ASCO
6d ago
2617
TransThera raises HK$152 million via H-share placing to fund Tinengotinib development
PremiumCompany Announcements
TransThera raises HK$152 million via H-share placing to fund Tinengotinib development
10d ago
2617
TransThera Sets 2026 AGM to Tackle Losses, Governance and New Share Mandate
PremiumCompany Announcements
TransThera Sets 2026 AGM to Tackle Losses, Governance and New Share Mandate
11d ago
2617
TransThera Wins China Phase II Trial Nod for Tinengotinib Combo in Resistant Prostate Cancer
PremiumCompany Announcements
TransThera Wins China Phase II Trial Nod for Tinengotinib Combo in Resistant Prostate Cancer
11d ago
2617
TransThera and Allist Launch Phase II Trial of TT-00973 and Firmonertinib Combo in EGFR-Mutant Lung Cancer
PremiumCompany Announcements
TransThera and Allist Launch Phase II Trial of TT-00973 and Firmonertinib Combo in EGFR-Mutant Lung Cancer
11d ago
2617
TransThera Calls June 2026 EGM to Approve New H Share Award Scheme
PremiumCompany AnnouncementsTransThera Calls June 2026 EGM to Approve New H Share Award Scheme
15d ago
2617
TransThera Sciences to Raise HK$156 Million via Discounted H-Share Placement
Premium
Company Announcements
TransThera Sciences to Raise HK$156 Million via Discounted H-Share Placement
18d ago
2617
TransThera reports promising tinengotinib results in advanced solid tumors
Premium
Company Announcements
TransThera reports promising tinengotinib results in advanced solid tumors
20d ago
2617
TransThera Raises HK$282 Million via H-Share Placing to Fund Cancer Drug Push
PremiumCompany Announcements
TransThera Raises HK$282 Million via H-Share Placing to Fund Cancer Drug Push
2M ago
2617
TransThera Showcases Tinengotinib Data on Endocrine Resistance in HR+ Breast Cancer at AACR 2026
PremiumCompany Announcements
TransThera Showcases Tinengotinib Data on Endocrine Resistance in HR+ Breast Cancer at AACR 2026
2M ago
2617
TransThera Starts Confirmatory Phase III Trial of Tinengotinib in Advanced Cholangiocarcinoma
PremiumCompany Announcements
TransThera Starts Confirmatory Phase III Trial of Tinengotinib in Advanced Cholangiocarcinoma
2M ago
2617
TransThera Sciences Launches Discounted HK$290 Million H-Share Placement
PremiumCompany Announcements
TransThera Sciences Launches Discounted HK$290 Million H-Share Placement
2M ago
2617
TransThera Sciences Proposes New H Share Award Scheme to Boost Equity Incentives
PremiumCompany AnnouncementsTransThera Sciences Proposes New H Share Award Scheme to Boost Equity Incentives
2M ago
2617
TransThera to Scrap Supervisory Committee in Governance Overhaul
Premium
Company Announcements
TransThera to Scrap Supervisory Committee in Governance Overhaul
2M ago
2617
TransThera Sciences reshapes board with independent director change
Premium
Company Announcements
TransThera Sciences reshapes board with independent director change
2M ago
2617
TransThera Sciences Sets Out Board and Committee Structure
PremiumCompany Announcements
TransThera Sciences Sets Out Board and Committee Structure
2M ago
2617
TransThera Sciences Widens Annual Loss Amid Continued R&D Spend
PremiumCompany Announcements
TransThera Sciences Widens Annual Loss Amid Continued R&D Spend
2M ago
2617
TransThera’s Tinengotinib Combo Trial Opens New Upside Optionality in Advanced Breast Cancer
PremiumCompany Announcements
TransThera’s Tinengotinib Combo Trial Opens New Upside Optionality in Advanced Breast Cancer
2M ago
2617
TransThera Schedules Board Meeting to Approve 2025 Annual Results and Potential Dividend
PremiumCompany Announcements
TransThera Schedules Board Meeting to Approve 2025 Annual Results and Potential Dividend
3M ago
2617
TransThera Starts Phase II Trial of Tinengotinib Combo in Hard-to-Treat Breast Cancer
PremiumCompany AnnouncementsTransThera Starts Phase II Trial of Tinengotinib Combo in Hard-to-Treat Breast Cancer
3M ago
2617
TransThera Sciences Added to Major Hang Seng Indexes, Exits Small-Cap Gauge
Premium
Company Announcements
TransThera Sciences Added to Major Hang Seng Indexes, Exits Small-Cap Gauge
3M ago
2617
TransThera Raises HK$190 Million via H-Share Placing to Fund Tinengotinib Trials and Pipeline R&D
Premium
Company Announcements
TransThera Raises HK$190 Million via H-Share Placing to Fund Tinengotinib Trials and Pipeline R&D
5M ago
2617

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >